Key Takeaways
- LSD, chemically known as (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide, has a molecular formula of C20H25N3O and a molecular weight of 323.43 g/mol
- The effective dose range for LSD is typically 20-150 micrograms, with full effects at 100-200 micrograms, producing profound alterations in perception and consciousness lasting 8-12 hours
- LSD binds primarily to serotonin 5-HT2A receptors with high affinity (Ki = 3.5 nM), acting as a partial agonist to induce hallucinogenic effects
- Albert Hofmann first synthesized LSD on November 16, 1938, while researching ergot alkaloids at Sandoz Laboratories in Basel, Switzerland, targeting circulatory and respiratory stimulants
- Hofmann accidentally discovered LSD's psychoactive effects on April 16, 1943, after absorbing a trace amount through his skin, experiencing restlessness and hallucinations during a bicycle ride home
- Sandoz Laboratories introduced LSD as a psychiatric drug under the name Delysid in 1947, recommending doses of 25 micrograms for analytical psychotherapy
- LSD induces visual hallucinations including geometric patterns, color enhancement, and synesthesia in 90-100% of users at doses above 75 micrograms
- Acute psychological effects of LSD include ego dissolution reported by 70% of users, profound time distortion, and mystical experiences akin to near-death states
- LSD increases brain connectivity, particularly between the default mode network and sensory regions, as shown in fMRI studies lasting up to 12 hours post-dose
- In 2019 surveys, lifetime LSD use among US adults aged 12+ was 1.4% (about 3.8 million people), with past-year use at 0.5%
- Among college students in 2022, past-year LSD use was 3.5%, higher among males (4.2%) than females (2.8%), per Monitoring the Future survey
- Global prevalence estimates indicate 1-2% of adults have tried LSD, with highest rates in Europe (e.g., 2.5% in Netherlands)
- LSD tolerance develops rapidly, with users needing 2-3x dose after 24 hours, fully resetting after 3-4 days of abstinence
- Long-term risks include Hallucinogen Persisting Perception Disorder (HPPD) affecting 4-10% of frequent users, with flashbacks lasting months to years
- LSD is non-addictive with no physical withdrawal, but psychological dependence rare at <1% in chronic users
LSD is a highly potent psychedelic with profound psychological effects and therapeutic potential.
Effects
Effects Interpretation
History
History Interpretation
Pharmacology
Pharmacology Interpretation
Risks
Risks Interpretation
Therapeutic
Therapeutic Interpretation
Usage
Usage Interpretation
Sources & References
- Reference 1PUBCHEMpubchem.ncbi.nlm.nih.govVisit source
- Reference 2EROWIDerowid.orgVisit source
- Reference 3NCBIncbi.nlm.nih.govVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5DEAdea.govVisit source
- Reference 6ENen.wikipedia.orgVisit source
- Reference 7HISTORYhistory.comVisit source
- Reference 8MAPSmaps.orgVisit source
- Reference 9UNODCunodc.orgVisit source
- Reference 10NATUREnature.comVisit source
- Reference 11JOURNALSjournals.sagepub.comVisit source
- Reference 12NIDAnida.nih.govVisit source
- Reference 13MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 14EMCDDAemcdda.europa.euVisit source
- Reference 15THEGUARDIANtheguardian.comVisit source
- Reference 16SAMHSAsamhsa.govVisit source
- Reference 17DEADIVERSIONdeadiversion.usdoj.govVisit source
- Reference 18JOURNALSjournals.plos.orgVisit source
- Reference 19CIAcia.govVisit source
- Reference 20PNASpnas.orgVisit source
- Reference 21CELLcell.comVisit source
- Reference 22GOVgov.ukVisit source
- Reference 23CANADAcanada.caVisit source
- Reference 24ERGOTISMergotism.orgVisit source
- Reference 25AIHWaihw.gov.auVisit source
- Reference 26JAMANETWORKjamanetwork.comVisit source
- Reference 27SIGMAALDRICHsigmaaldrich.comVisit source
- Reference 28GLOBALSMARTglobalsmart.orgVisit source
- Reference 29LATIMESlatimes.comVisit source
- Reference 30IMPERIALimperial.ac.ukVisit source
- Reference 31SBSsbs.com.auVisit source
- Reference 32WHOwho.intVisit source





